News

Aegis Sciences and McNabb Center Team Up Against Opioid Crisis

Aegis Sciences and McNabb Center Team Up Against Opioid Crisis

Aegis Sciences and the McNabb Center Collaborate

Aegis Sciences Corporation has embarked on an important partnership with The McNabb Center to investigate the effects of xylazine on individuals experiencing opioid withdrawal. This collaboration comes in response to a pressing need for more effective treatment approaches amid the evolving landscape of substance use disorders.

Understanding the Challenge of Xylazine

Recently, the White House highlighted xylazine alongside fentanyl as an emerging threat to communities across the country. Xylazine, not approved for human use, intensifies certain risks associated with opioid addiction and is becoming increasingly prevalent in the drug supply. Dr. Ryan Alexander, a prominent figure in addiction medicine, observed that traditional methods of managing opioid withdrawal were often falling short due to these new challenges.

Dr. Alexander’s Observations

Dr. Alexander, who serves as the medical director for substance use disorder services at the McNabb Center, noticed a troubling trend: patients admitted for opioid withdrawal were exhibiting withdrawal symptoms beyond what was typical. A deeper dive into the role of xylazine in the drug landscape seemed vital to better understand and treat these patients.

Setting Up the Collaboration

In 2021, Aegis established testing protocols for detecting xylazine in urine and oral fluid samples from individuals undergoing treatment. This initiative piqued Dr. Alexander's interest due to its relevance in understanding recent drug use patterns among patients. The partnership blossomed from this initial spark of interest, aiming to enhance the understanding of treatment efficacy in dealing with the interaction of xylazine and opioids.

Expert Insights from Aegis Sciences

Dr. Josh Schrecker, the Sr. Director of Clinical Affairs at Aegis, expressed enthusiasm for the collaboration. He remarked that the partnership would not only assist in clinical research but also contribute significantly to care management strategies in the current landscape marred by increasing substance abuse.

Publication of Findings

Recent research titled "Withdrawal Signs and Symptoms Among Patients Positive for Fentanyl With and Without Xylazine" has shed light on the concerning rise in co-use of fentanyl and xylazine. This research, published in a respected journal, reinforces the need for adjusted treatment protocols. Patients who had exposure to both drugs showed higher instances of self-directed discharges, indicating they were unable to complete their treatment plans.

The Role of Xylazine in Treatment Outcomes

This ground-breaking research brings into question the current strategies in opioid withdrawal management. The increase in xylazine's presence in the drug supply could dictate a need for re-evaluation of treatment approaches, pushing healthcare providers to adapt to these new realities.

The Commitment of Aegis Sciences Corporation

Aegis Sciences Corporation is dedicated to delivering thorough and innovative testing solutions, offering critical insights to healthcare professionals dealing with substance use disorders. The firm has a long-standing history of supporting both individual and community health.

About Aegis Sciences Corporation

Founded in 1990, Aegis is committed to providing extensive laboratory services across the United States. Serving a diverse clientele, including healthcare professionals and governmental bodies, Aegis strives to advance the understanding of substance use disorders through science-driven approaches.

About The McNabb Center

As a leading nonprofit organization in East Tennessee, The McNabb Center offers a wide array of services for mental health and substance use. Their mission focuses on ensuring that individuals receive compassionate and comprehensive care, addressing the complexities of substance use and recovery. With a proud history dating back to 1948, the Center impacts thousands of lives every year, promoting wellness and recovery among the vulnerable populations.

Frequently Asked Questions

What is the main purpose of the Aegis Sciences and McNabb Center collaboration?

The collaboration aims to evaluate the impact of xylazine exposure on individuals undergoing treatment for opioid use disorder.

Why is xylazine a concern in opioid treatment?

Xylazine can exacerbate withdrawal symptoms and complicate traditional opioid withdrawal management strategies.

What did Dr. Alexander notice about opioid withdrawal treatments?

Dr. Alexander observed that standard methods for managing withdrawal symptoms were becoming less effective for some patients.

How does Aegis Sciences contribute to the treatment of substance use disorders?

Aegis Sciences provides critical testing services that help healthcare providers make informed treatment decisions based on recent substance use.

What role does The McNabb Center play in opioid addiction recovery?

The McNabb Center delivers comprehensive mental health and substance use services, emphasizing compassionate care and support for those in need.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 92

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 272

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 49

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 233

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 92

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 187

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 211

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading

Top 5 Most Recently Viewed Articles

Atlantic International Corp. Achieves Major Contract Success

Updated Category News Views 124

Atlantic International Corp. Secures Major Contract for Growth Atlantic International Corp. (Nasdaq: ATLN), a prominent player in the field of strategic staffing, recently achieved a significant milestone through its subsidiary, Lyneer Staffing Solutions. This achievement comes in the form of a multi-million dollar manufacturing contract with a leading food manufacturer....

Continue Reading
Santa Cruz County's Bold Move Against Cigarette Filters

Updated Category News Views 144

Santa Cruz County's Bold Action Against Cigarette Filters In a landmark decision, Santa Cruz County has become the first jurisdiction globally to implement a ban on the sale of cigarettes with filters. This crucial measure aligns perfectly with the upcoming World No Tobacco Day, highlighting the county's commitment to both public health and environmental sustainability....

Continue Reading
OceanaGold Embraces New Fast-Track Approvals for Growth

Updated Category News Views 154

OceanaGold Welcomes New Fast-track Approvals Act OceanaGold Corporation (TSX: OGC) (OTCQX: OCANF) has embraced the recent passing of the Fast-track Approvals Act by the New Zealand Parliament. This important legislative move is designed to streamline the consenting process for regionally and nationally significant infrastructure and development projects. With this new...

Continue Reading
Why Debt Repayment Spreadsheets Fail and How to Get Out of Debt

Updated Category Personal Finance Views 113

We have all been told the same basic formula for clearing negative balances: list your liabilities from smallest to largest, choose between the avalanche or snowball method, and cut your spending to the bone. On paper, a debt payoff journey looks like a straightforward mathematical equation. But if you have ever spent a weekend building a beautiful, co

Continue Reading
Elis Reports Own Shares Trading Activity and Future Plans

Updated Category News Views 232

Elis Shares Trading Activity Overview Elis has recently engaged in noteworthy trading activities concerning its own shares. As part of this initiative, Elis has executed buybacks of its own shares under a designated program authorized by the company's shareholders. Details of Recent Share Buybacks According to updated regulations on share buybacks, Elis conducted several...

Continue Reading